Ethics approval for Pharmaceuticals Receives' new diabetic foot ulcer study

Recce Pharmaceuticals (ASX:RCE) has announced that it has received Human Research Ethics Committee (HREC) approval to start its Phase 1/2 clinical trial assessing R327 as a spray-on, broad-spectrum antibiotic therapy for mild skin and soft tissue diabetic foot infections. …